The present invention relates to the branch of biotechnology and more specifically to human health. Particularly, the present invention describes a vaccine composition for therapeutic use in cancer patients. The vaccine composition described in the present invention has as its active ingredient a chemical conjugate between the recombinant Human Epidermal Growth Factor (hrEGF) and the recombinant protein P64k. In addition, specific conditions for carrying out a conjugation reaction are described which allow obtaining said chemical conjugate in a controlled and reproducible manner. In another aspect the present invention relates to a method for the purification of the chemical conjugate that not only brought greater purity to the therapeutic vaccine composition, but also surprisingly increased immunogenic activity, causing significant increases in anti-EGF antibody titres in humans. Additionally, the present invention provides the methodology for achieving a vaccine preparation with more than one type of dose presentation (total milligrams of EGF-P64k / vial conjugates). This versatility in the presentation of the vaccine preparation allows to increase the dose of immunization per patient, without this leading to increasing the frequency of immunization and / or the number of immunization sites. Finally, the present invention involves a sanitary procedure for obtaining the vaccine preparation for cancer therapy, administered parenterally.La presente invención se relaciona con la rama de la biotecnología y mas específicamente con la salud humana. Particularmente, lapresente invención describe una composición vacunal para su uso terapéutico en pacientes de cáncer. La composición vacunal descrita en la presente invención tiene como principio activo un conjugado químico entre el Factor de Crecimiento Epidérmico humano recombinante (hrEGF) y la proteína recombinante P64k. Además, se describen condiciones específicas para la realización de una reacciónde conjugación que per
